Reducing Opioid Risk Act

Bill: 115-s-2608
Sponsor: full_name: Sen. Warren, Elizabeth [D-MA]
Introduced: 2018-03-22
Policy area: Health
Subjects: Drug safety, medical device, and laboratory regulation

Drug trafficking and controlled substances

Health personnel

Prescription drugs
Latest action: action_date: 2018-03-22
text: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summaries:
action_date: 2018-03-22
action_desc: Introduced in Senate
text: <p><b>Reducing Opioid Risk Act</b></p> <p>This bill amends the Federal Food, Drug, and Cosmetic Act to expand the authority of the Food and Drug Administration to require a drug manufacturer to inform health care providers about state and federal regulations for controlled substances, including the partial fill option.</p>

tv_txt: II 115th CONGRESS 2d Session S. 2608 IN THE SENATE OF THE UNITED STATES March 22, 2018 Ms. Warren (for herself and Mrs. Capito ) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL To provide that a risk evaluation and mitigation strategy communication plan may include information about Federal and State prescribing requirements for controlled substances.

1. Short title This Act may be cited as the Reducing Opioid Risk Act . 2. Risk evaluation and mitigation strategy communication plans Section 505–1(e)(3) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355–1(e)(3) ) is amended— (1) in subparagraph (B), by adding a semicolon at the end; (2) in subparagraph (C), by striking ; or and inserting a semicolon; (3) in subparagraph (D), by striking the period and inserting ; or ; and (4) by adding at the end the following: (E) disseminating information to health care providers about Federal and State prescribing requirements for controlled substances, including the requirements under section 309(f) of the Controlled Substances Act, as applicable. .